Christopher Cooper
Optometrist · Memphis, TNNPI 1770529125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $389 and has fallen 86.7% since, to $52 in 2025.
Across 21 payments — averaging $49.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$205
- Johnson & Johnson Vision Care, Inc.$189
- Sight Sciences, Inc.$120
- Harrow Eye, LLC$118
- Shire North American Group Inc$118
- Carl Zeiss Meditec, Inc.$99
- plus $193 from 4 others
Across 47 payments — averaging $40.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$2K
What the payments were for
- Food & beverage$1,042100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $205 |
| Johnson & Johnson Vision Care, Inc. | 6 | $189 |
| Sight Sciences, Inc. | 1 | $120 |
| Harrow Eye, LLC | 1 | $118 |
| Shire North American Group Inc | 1 | $118 |
| Carl Zeiss Meditec, Inc. | 1 | $99 |
| Abbott | 1 | $94 |
| Bausch & Lomb Americas Inc. | 3 | $58 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Oyster Point Pharma, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$130
- OMNI(R) SURGICAL SYSTEM (US)$120
- VEVYE$118
- XIIDRA$118
- Acuvue$117
How this compares
$1,042 in reported general payments places this provider in the 60th percentile of 1,122 optometrist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 171 | $127,788 |
| LumiganBimatoprost | 214 | $81,827 |
| RocklatanNetarsudil Mesylat/Latanoprost | 130 | $57,079 |
| XiidraLifitegrast | 54 | $38,565 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 90 | $19,875 |
| VyzultaLatanoprostene Bunod | 42 | $16,038 |
| Cyclosporine | 40 | $14,802 |
| CombiganBrimonidine Tartrate/Timolol | 45 | $14,266 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 54 | $7,095 |
| Brimonidine Tartrate | 63 | $6,466 |
| RhopressaNetarsudil Mesylate | 14 | $5,749 |
| Latanoprost | 498 | $4,521 |
| Travoprost | 37 | $3,186 |
| Loteprednol Etabonate | 12 | $1,921 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 142 | $1,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $205 | $223,880430 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $58 | $54,60396 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $21 | $1,92112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,122 optometrist providers in Tennessee.
Other optometrist in Memphis
- Christopher LievensMemphis$566K
- Whitney HauserMemphis$330K
- Melvin FriedmanMemphis$108K
- Desirae BrinkleyMemphis$51K
- Abagail KirkMemphis$14K
- Bradley HinesMemphis$12K
- David EvansMemphis$12K
- Daniel FullerMemphis$8K
- Dennis MathewsMemphis$8K
- Michael GerstnerMemphis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.